Skip to content

The Role of Indocyanine Green to Identify Sentinel Lymph Node in Uterine Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02822833
Enrollment
100
Registered
2016-07-04
Start date
2016-07-31
Completion date
2017-06-30
Last updated
2016-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Neoplasm

Brief summary

Endometrial cancer is the most common gynecologic malignancy in developed countries and the second one in developing countries following cervical cancer. The primary treatment for endometrial cancer involves total hysterectomy and bilateral salpingo-oophorectomy, with adjuvant radiotherapy and/or chemotherapy reserved for patients with advanced disease or who have risk factors for relapse. The tumor is confined to the uterus in 85% of endometrial cancers. Hence, it's controversial to perform systematic lymphadenectomy to all patients. The primary purpose of the present study is the to investigate the feasibility of sentinel lymph node determination in endometrial cancer patients operated via conventional laparoscopy. To determine sentinel lymph nodes cervical indocyanine green will be injected prior to the surgery. During the surgery using fluorescent imaging systems sentinel lymph nodes will be removed and examined by frozen section. Afterwards, systematic pelvic lymphadenectomy will be performed. In case of type II endometrial cancer, grade 3, metastatic sentinel lymph nodes or macroscopically enlarged paraaortic lymph nodes, paraaortic lymphadenectomy will also be performed. The secondary purpose of the study is to compare the conventional laparoscopy in sentinel lymph node mapping of endometrial cancer patients.

Interventions

Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.

Sponsors

Ankara University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pathologic diagnosis of endometrial cancer * Clinical stage I or II

Exclusion criteria

* Contraindications for operation (hematological or coagulation disorders) * Advanced stage * Pregnancy or puerperium * Fertility preserving surgery

Design outcomes

Primary

MeasureTime frame
Sensitivity and specificity of sentinel lymph node frozen section6 months
Unilateral or bilateral sentinel lymph node detection rate by indocyanine green6 months

Secondary

MeasureTime frame
Negative and positive predictive values for sentinel lymph node frozen section6 months

Countries

Turkey (Türkiye)

Contacts

Primary ContactSalih Taşkın, Assoc. Prof.
salihtaskin@yahoo.com+903125956405

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026